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Abstract 
Many Americans are either currently taking, or have recently taken, non-prescription dietary 
supplements. These supplements claim to help prevent or relieve any number of ailments, but 
are not regulated by any governing body. One common use of dietary supplements is to aid in 
weight loss. Synephrine, the most abundant active component in bitter orange (Citrus aurantium 
L.) extracts, became a regular ingredient in weight loss supplements after the 2004 ephedra ban. 
The initial goal of this research was to use reverse phase high performance liquid 
chromatography (HPLC) to determine the synephrine content of five dietary supplements and 
compare to the reported content on the label. However, due to difficulties I encountered with the 
HPLC instrument, I instead used NanoDrop Spectrophotometry to analyze synephrine content. 
This technique was not as precise as HPLC, but data were obtained that indicated the 
supplements contained significantly less synephrine than the standard (1-Way ANOVA, 
F421=60.042, P=<0.001). Additionally, my analysis indicated that the supplements had a lower 
concentration of synephrine than what was reported on their labels. 
 
Introduction 
The use of non-prescription dietary supplements is common among American consumers (Blank 
et al. 2007). The Food and Drug Administration (FDA) has rules and guidelines for accurate 
labeling of foods in relation to claims regarding health, nutrient content, and structure/function 
(Food and Drug Administration 2003). However, dietary supplement labels include a statement 
saying, “These claims have not been evaluated by the FDA. This product is not intended to 
diagnose, treat, cure, or prevent any disease.” While the FDA has general warnings about 
dietary supplement use, the agency is not responsible for the regulation of dietary supplements 
due to the Dietary Supplement Health and Education Act of 1994 (US Public Law 103-417), in 
which supplements were defined as dietary ingredients, not as foods. The United States 
Pharmacopeial (USP) Convention has a dietary supplement verification program which offers 
voluntary testing to verify ingredients, to confirm a lack of contaminants, and to audit 
manufacturing practices (United States Pharmacopeial Convention 2012). However, few 
companies have taken advantage of this program and most products bearing the USP seal of 
verification are vitamins and minerals. Because they are not subject to mandatory governmental 
oversight, consumers are required to trust that the manufacturer’s label contains an accurate 
description of the product, its uses and how it affects the human body. 
While dietary supplements can be taken for a variety of purposes, one of the more common uses 
is to aid in weight loss. Approximately 30% of the United States is currently obese and three out 
of five adults are overweight, as determined by body mass index (Haaz et al. 2006). Weight loss 
supplements are a popular alternative to diet and exercise, bariatric surgery or other more 
invasive weight-loss techniques (Haaz et al. 2006). Ephedra-based supplements were widely 
used for weight loss and increased exercise performance until 2004 when ephedra was banned by  
the FDA due to adverse cardiovascular events associated with its use (Gange et al. 2006). 
Following this ban, manufacturers started marketing “ephedra-free” supplements that could give 
consumers the same weight loss and performance enhancement as ephedra without the adverse 
side effects (Haller et al. 2008). Bitter orange (Citrus aurantium L.) is one of the “ephedra-free” 
supplements that gained popularity shortly after the ban. Bitter orange is native to eastern 
African and tropical Asia, and has been introduced to Florida, California, and the Mediterranean 
region. It has been used in traditional Chinese medicine for gastrointestinal problems and, in 
addition to weight loss, is currently used to treat heartburn, congestion, and paradoxically, to 
increase appetite (Fugh-Berman and Myers 2004). 
Synephrine is the most abundant active compound in bitter oLnas, and is frequently used in 
“performance stacks” that pair synephrine with other stimulants and non-steroidal anti- 
inflammatory drugs (Thomas et al. 2009). Manufacturers claim the compound promotes weight 
loss by reducing appetite, burning fat, increasing metabolism and energy, and/or having 
thermogenic properties. Synephrine is an a- and B-adrenergic antagonist and is structurally 
similar to ephedrine; however the cardiovascular effects have not been studied in great detail 
(Thomas et al. 2009). Synephrine, like ephedra, is a sympathomimetic, and its use has been 
linked to cases of variant angina (Gange et al. 2006), myocardial infarction, hypertension, 
(Thomas et al. 2009), and stroke (Bouchard et al. 2005) in otherwise active and healthy persons. 
The normal recommended dose is between 10 mg three times daily and 20 mg once daily, and it 
is commonly sold as a nearly pure powder or in capsules. Some capsules contain synephrine 
stacks for weight loss and others only contain bitter orange extract with a stated percentage of 
synephrine.  
The purpose of this research is to determine the synephrine content of five dietary supplements 
reported to contain synephrine using high performance liquid chromatography (HPLC). The 
quantified amount of synephrine will be compared to the reported values on supplement labels. 
Materials and Methods 
HPLC 
Materials 
Five synephrine supplements were included in this study: Synephrine HCI 99% Bulk Powder 
(Build Your Own Supplements, York, PA), SyneBURN 100% Synephrine HCI (PrimaFORCE, 
Burlington, NC, Bitter Orange Herb 120 mg Capsule (unknown synephrine, Solaray, Park City, 
UT), Bitter Orange Standardized Extract (6% synephrine, Nature’s Way, Lehi, UT). A pure 
synephrine standard (>98% synephrine) was obtained from Sigma-Aldrich (St. Louis, MO). In 
addition, 4-(dimethylamino)pyridine, also from Sigma-Aldrich was to be used as an internal 
standard to improve quantification precision. 
Sample Preparation and Synephrine Extraction 
All extractions and preparations were conducted in glassware to avoid contaminating the organic 
solvents with plastic. Additionally, a bottle of working methanol was used for dilutions and 
extractions to avoid contaminating the methanol stock. 
To prepare my standard, I measured 1mg of the >98% synephrine and dissolved it in mL 
HPLC-grade methanol. This was then used as the stock solution for a serial dilution, wherein the 
most dilute sample was 0.5pug/mL. The same serial dilution plan was followed for 4- 
(dimethylamino)pyridine, our internal standard.  
Supplement capsules were opened, the mass was determined, and contents were combined to 
reach a total of 1g of material for each supplement. Tablets were prepared with a mortar and 
pestle and also combined to reach 1g of material. Synephrine was extracted following methods 
outlined in Arbo et al. (2008). In short, 4 mL of methanol was added and then samples were left 
at room temperature for 20 min. Afterwards, samples were centrifuged at 3,000 rpm for 15 min 
and then filtered through 2 A syringe filters (National Scientific Company, Rockwood, TN). The 
extraction procedure was repeated for each sample and the first and second extracts were 
combined. A total of ten extracts were prepared for each supplement. 
Chromatography 
My plan was to identify the synephrine peak by comparing its retention time on the HPLC 
column with that obtained from the pure standard. I also planned to calculate the concentration 
of synephrine in samples by creating a calibration curve using known concentrations of the 
synephrine standard. 
The details of HPLC method used were as follows: 20uL of each sample was injected into an 
Agilent 1100 HPLC system fitted with a C-18 column (150 x 4.6 mm i.d., 5 um, Agilent 
Technologies, Santa Clara, CA) and a C-18 guard column (Phenomenex, Torrance, CA, method 
summarized in Table 1). The mobile phase A consisted of acetonitrile-water-trifluroacetic acid 
(5:95:0.01, v/v/v). Mobile phase B was pure acetonitrile. Gradient elution followed that 
outlined in Arbo et al. (2008): 0-8 min with 100 — 59% A, 8-10 min with 59 — 0% A, 10-12 min 
0% A, 12-13 min 0-100% A, 13-18 min with 100% A, all at a constant flow rate of 0.6 mL/min. 
Synephrine was detected by UV absorption at 220 nm. The synephrine peak in the supplements 
was to be identified by comparing peak retention times with that obtained from the pure 
standard. To calculate the concentration of synephrine in samples, I intended to create a 
calibration curve using known concentrations of the synephrine standard. 
NanoDrop Spectrophotometry 
Materials 
All supplements and standards for this analysis were the same as have already been described 
above. The internal standard, 4-(dimethylamino)pyridine, was not required for this analysis. 
Sample Preparation and Synephrine Extraction 
The synephrine standard was prepared in a similar manner as described above, in that a Img 
sample was dissolved in 1mL HPLC-grade methanol. The dissolved sample was vortexed for 1 
min, and 100puL was moved to a separate vial and left to dry overnight. 
Supplement samples were measured out to 1g, and extracted with 500uL methanol by using the 
extraction protocol described above. A second extraction was completed for each supplement, 
and the extracts were combined for a total of 1mL methanol per sample. The total volume was 
vortexed for 1 min, and 100pL was moved to a separate vial and left to dry overnight. 
After drying, all samples were dissolved in 100uL of water and vortexed for 3 min. The final 
dilution for each supplement and the standard varied slightly due to differences in absorptivity 
(Table 2). Samples were vortexed after each subsequent dilution. 
 
Statistical Analysis 
Upon completion of the spectrophotometry analysis, collected data were analyzed in SPSS using 
a One-Way ANOVA. Additionally, the coefficient of variation was calculated in Excel to 
determine the amount of variation that occurred across subsamples of each supplement. 
Results 
HPLC 
Data were unable to be obtained using HPLC. Due to problems with the available HPLC, both 
synephrine and the internal standard had nearly identical chromatograms (Fig 1). Based on a 
paper by Takei et al. (1999), synephrine should have come off the column at approximately 9 
min, and pyridine should have come off at least 1 min before. To correct for any introduced 
error or contamination, the samples were remixed with new solvent and only glassware was used 
for transfer and storage of solvents and dilutions. Additionally, a new, factory-clean column was 
put on the instrument and the guard column was changed. Before injecting synephrine, the 
column was rinsed with 100% methanol (Fig. 2a). A trial run with 4pug synephrine in methanol 
was then conducted (Fig. 2b). Due to the difficulties I encountered, it was decided to use 
NanoDrop Spectrophotometry to complete the analysis in place of HPLC. 
NanoDrop Spectrophotometry 
The NanoDrop spectrophotometer measures absorbance along a continuous wavelength gradient 
from 220-750nm (Fig. 3). An ANOVA was conducted to determine if there were significant 
differences between supplements and the standard. Post-hoc tests revealed significant 
differences across the supplements (1-Way ANOVA, F4,,=60.042, P=<0.001, Figure 4). The 
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coefficient of variation was high for all samples, including the standard (Table 3). However, the 
coefficient of variation within the subsamples was much lower than the overall sample variation 
(Table 4). A composite graph for 10 samples is shown in Fig. 5. 
Discussion 
The initial objective of this research was to use HPLC to quantify the synephrine concentration 
in a variety of commercial supplements and to compare the concentrations that I obtained with 
those reported by the manufacturers on the supplement labels. However, during HPLC method 
development, I encountered several problems. Without running a sample through the column, 
the instrument consistently showed a peak at 2.5-3 min. It was decided to move ahead with 
obtaining calibration curves for the standards, as the unidentified peak did not overlap with the 
time that synephrine and pyridine were expected to show on the chromatogram. The 
chromatograms for these trials are shown in Figures 1 and 2. After changing the column, guard 
column and attempting to correct for potential introduced error, the chromatograms shown in 
Figures 3 and 4 were obtained from an injection of pure methanol and a synephrine trial, 
respectively. 
The problems encountered with the HPLC may be attributed to a number of factors. The major 
contributors seem to be the unknown instrument history and unknown column history. The 
instrument is housed in a different department, and has been used primarily for basic classroom 
work for a number of years. It had recently been certified clean by the manufacturer, but there 
may have been some residual compound in the injection loop or elsewhere within the instrument 
that reacted with the solvents used in this method. Similarly, the first column used was donated 
by an outside pharmaceutical lab. It is not known what the column was used for in the past or  
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what solvents had been run through it. However, if the history of the column results in the 
problems I encountered, then they should have been resolved when I switched to using a brand 
new column, which was not the case. Due to time constraints, it was decided to instead quantify 
the synephrine content using a NanoDrop Spectrophotometer. With this different method there 
was no need for an internal standard, so the data reported only include the four supplements and 
synephrine standard. As noted, a very high coefficient of variation was calculated for all 
samples using this method, including the standard. With the standard, this may be explained by 
the tiny amount used for the analysis. A Img sample was measured out on a balance that read to 
0.Img. Because of the small amount needed and relatively imprecise balance used, any 
fluctuations in mass across the samples would have caused high variation in absorbance. 
This cannot explain the high variation in the supplements, however, as those were measured to 
1g on a balance that read to 0.001g. One potential source of added variation is contaminants in 
the capsules and tablets. If there were other fillers or compounds in the supplements that 
dissolved in methanol, those would have been extracted with the synephrine and may have 
interfered with synephrine absorption. If more extraneous compounds were extracted in some 
sub-samples than others, those would have higher absorption and could contribute to the high 
variation. It is possible there was variable synephrine content across the capsules which 
contributed to the calculated variation, although I would not have expected the variation to be as 
high as was present. Variation within each sub-sample was low in most cases; it only became 
high when all sub-samples were averaged together. Another source of variation may be from 
how well water redissolved the synephrine following extraction. If synephrine was unable to 
fully dissolve in some of the sub-samples, it would have decreased overall absorbance and led to 
an increase in variation.  
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Variation may also have been introduced when taking absorption measurements. The method 
developed for HPLC analysis had synephrine detection set at 220nm. The spectrophotometer 
used for this research was able to detect at that wavelength, but it was at the low extreme for the 
instrument. Absorption was instead detected at 230nm and 240nm, with the decision that the 
measurements at 230nm would be used as the synephrine absorbance. In my absorbance graphs 
it was apparent that the maximum absorbance for my samples occurred at 220 — 225nm, with the 
line for 230nm falling on the down slope of the absorbance curve (Fig. 3). Variance may have 
been introduced if the slope of the curve changed slightly across samples or sub-samples (Fig. 5). 
This figure shows the composite graphs for Nature’s Way, though some other samples are 
included in the composite and can be ignored for the purposes of this discussion. Many of the 
graphs are very similar, as I would expect if they are from the same supplement. However, small 
changes to the height of the peak would alter the rate of change on the slope, thereby affecting 
the measured absorbance at that point. 
[ had planned to quantify the synephrine content in the tested supplements. The 
spectrophotometer is not as precise an instrument as HPLC, but absorption for supplements as 
compared to the standard could be used as a rough quantification. However, the variation was so 
high that I determined quantification would not produce meaningful data. 
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Tables and Figures 






         
siren! Agilent 1100 HPLC 
Coli C-18 column (150 x 4.6 mm i.d., 5 um, Agilent 
Technologies, Santa Clara, CA) and a C-18 guard 
column (Phenomenex, Torrance, CA). 
Mobile Phase A Acetonitrile: water:trifluroacetic acid (5:95:0.01, 
v/viv) 
Mobile Phase B HPLC Grade Acetonitrile 
Minutes 9% A %B 
0 100 0 
8 59 41 
Gradient 
10 0 100 
Arbo et al. (2008) 
12 0 100 
13 100 0 
18 100 0 
Injection Volume 20uL 
Flow Rate 0.6mL/min 
Detection 220nm UV       
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Table 2: For spectrophotometry, a stock solution was mixed with a known synephrine 
concentration. These solutions were diluted with water until I found a concentration that was 
able to be measured by the instrument. The dilutions in the third column are the 




        
Dilution for Amount in final 
Sample ID Stock NanoDrop sample 
Standard lpg/ul 0.25pug/uL 0.75ug 
Solaray 100pg/uL 6.7ug/ul 20ug 
Nature's Way | 100pg/uL 10pg/uLL 30ug 
SyneBURN | 100ug/uL 20ug/ul 60ug 




Table 3: Overall mean absorbance per gram, standard deviation, and coefficient of variation for 
each supplement. 
 
   
Supplement Mean (abs/g) | Standard Deviation | Coefficient of Variation 
Standard 0.8343 0.1838 22% 
Solaray 0.0713 0.0171 24% 
Nature's Way 0.0362 0.0151 41% 
SyneBURN 0.0202 0.0035 17% 
Bulk Powder 0.1811 0.0566 31%         
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Table 4: Mean absorbance per gram, standard deviation, and coefficient of variation for each 
sub-sample. Solaray, Nature’s Way and SyneBURN had 6 sub-samples analyzed each, while the 
standard and Bulk Powder each had 4 sub-samples. 
  










         
Mean Standard Coefficient of 
Sub-Sample (abs/g) Deviation Variation 
Standard 
A 1.033 0.0038 0.4% 
B 0.9683 0.0208 2.1% 
C 0.5607 0.004 0.7% 
D 0.7763 0.0101 1.3% 
Solaray 
A 0.0564 0.0012 2.1% 
B 0.065 0.004 6.2% 
C 0.046 0.0009 1.9% 
D 0.0857 0.0064 7.5% 
E 0.0799 0.0057 7.1% 
F 0.0813 0.0026 3.2% 
Nature's Way 
A 0.04 0.0024 6.0% 
B 0.0277 0.0009 3.2% 
C 0.0196 0.0005 2.6% 
D 0.0193 0.0004 2.1% 
E 0.0554 0.0026 4.7% 
F 0.0515 0.0006 1.2% 
SyneBURN 
A 0.0279 0.0003 1.1% 
B 0.0189 0.0012 6.3% 
Cc 0.1932 0.0003 0.2% 
D 0.0182 0.0013 7.1% 
E 0.0187 0.0009 4.8% 
F 0.0181 0.0006 3.3% 
Bulk Powder 
A 0.1698 0.0012 0.7% 
B 0.155 0.0032 2.1% 
C 0.1246 0.0019 1.5% 
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Figure 1: The chromatogram in a is from a 2ug synephrine sample, while b is from a 3ug sample 
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Figure 2: The chromatogram in a is from an injection of pure methanol in a new column. A run 
with 4pg synephrine was then conducted, resulting in the chromatogram in b. As before, the 
chromatograms from both trials were the same. 
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Figure 3: This graph indicates absorbance of a sample along a continuous wavelength gradient 
using the NanoDrop spectrophotometer. Absorbance was specifically recorded at 230nm and 
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Figure 4: Spectrophotometer absorbance (+/- 1S.E.) across the supplements and standard. 
Letters above the bars denote significance, in that bars with a common letter are not significantly 
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